Stuttgart - Delayed Quote EUR

Oncimmune Holdings plc (OCY.SG)

Compare
0.1330
-0.0050
(-3.62%)
At close: 4:00:24 PM GMT+1
Currency in GBP All numbers in thousands
Download
Breakdown
TTM
8/31/2023
5/31/2022
5/31/2021
5/31/2020
Total Revenue
1,152.0000
1,152.0000
3,206.0000
3,722.0000
509.0000
Cost of Revenue
360.0000
360.0000
1,749.0000
865.0000
537.0000
Gross Profit
792.0000
792.0000
1,457.0000
2,857.0000
-28.0000
Operating Expense
5,160.0000
5,160.0000
10,043.0000
8,074.0000
9,855.0000
Operating Income
-4,368.0000
-4,368.0000
-8,586.0000
-5,217.0000
-9,883.0000
Net Non Operating Interest Income Expense
-1,800.0000
-1,800.0000
-943.0000
-1,315.0000
-515.0000
Pretax Income
-5,928.0000
-5,928.0000
-9,529.0000
-6,060.0000
-9,783.0000
Tax Provision
223.0000
223.0000
-17.0000
-1,068.0000
-1,324.0000
Net Income Common Stockholders
4,104.0000
4,104.0000
-9,512.0000
-4,992.0000
-8,459.0000
Diluted NI Available to Com Stockholders
4,104.0000
4,104.0000
-9,512.0000
-4,992.0000
-8,459.0000
Basic EPS
0.06
0.06
-0.14
-0.08
-0.13
Diluted EPS
0.06
0.06
-0.14
-0.08
-0.13
Basic Average Shares
72,574.8960
72,508.8340
69,430.6570
64,571.1800
63,300.1830
Diluted Average Shares
72,574.8960
72,508.8340
69,430.6570
64,571.1800
63,300.1830
Total Operating Income as Reported
-3,924.0000
-3,924.0000
-8,586.0000
-5,145.0000
-9,268.0000
Total Expenses
5,520.0000
5,520.0000
11,792.0000
8,939.0000
10,392.0000
Net Income from Continuing & Discontinued Operation
4,104.0000
4,104.0000
-9,512.0000
-4,992.0000
-8,459.0000
Normalized Income
-6,151.0000
-6,151.0000
-9,512.0000
-5,051.3109
-8,990.7679
Interest Income
--
--
--
3.0000
111.0000
Interest Expense
516.0000
516.0000
943.0000
837.0000
314.0000
Net Interest Income
-1,800.0000
-1,800.0000
-943.0000
-1,315.0000
-515.0000
EBIT
-5,412.0000
-5,412.0000
-8,586.0000
-5,223.0000
-9,469.0000
EBITDA
-4,431.0000
-4,431.0000
-7,157.0000
-4,483.0000
-8,969.0000
Reconciled Cost of Revenue
360.0000
360.0000
1,749.0000
865.0000
537.0000
Reconciled Depreciation
981.0000
981.0000
1,429.0000
740.0000
500.0000
Net Income from Continuing Operation Net Minority Interest
-6,151.0000
-6,151.0000
-9,512.0000
-4,992.0000
-8,459.0000
Total Unusual Items Excluding Goodwill
--
--
--
72.0000
615.0000
Total Unusual Items
--
--
--
72.0000
615.0000
Normalized EBITDA
-4,431.0000
-4,431.0000
-7,157.0000
-4,555.0000
-9,584.0000
Tax Rate for Calcs
0.0002
0.0002
0.0000
0.0002
0.0001
Tax Effect of Unusual Items
--
--
--
12.6891
83.2321
5/31/2020 - 8/28/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AXIM AXIM Biotechnologies, Inc.
0.0031
+14.81%
 
INVA Innoviva, Inc.
18.79
-1.00%
 
IGMS IGM Biosciences, Inc.
1.5800
-4.82%
 
KYMR Kymera Therapeutics, Inc.
40.65
-1.38%
 
LEGN Legend Biotech Corporation
36.01
-1.72%
 
IOVA Iovance Biotherapeutics, Inc.
6.19
-0.96%
 
CRSP CRISPR Therapeutics AG
41.81
-0.10%
 
RXRX Recursion Pharmaceuticals, Inc.
7.43
+5.69%